Incidence of cervical disease associated to HPV in human immunodeficiency infected women under highly active antiretroviral therapy

Infectious Agents and Cancer

Volumn 4, Issue 1, 2009, Pages

  Mogtomo, Martin Luther Koanga ^a   Malieugoue, Louise Carole Gouabe ^a   Djiepgang, Carolle ^a   Wankam, Michel ^b   Moune, Andre ^c   Ngane, Annie Ngono ^a  

^a UNIVERSITY OF DOUALA   (Cameroon)

^b Aids Care Unit and Gynaecology   (Cameroon)

^c DOUALA GENERAL HOSPITAL   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CAMEROON; CANCER INCIDENCE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIFESTYLE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VENOUS BLOOD; WART VIRUS;

EID: 68149100006     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-4-9     Document Type: Article

References (30)

1. The viral etiology of cervical cancer. FX Bosch N Munoz, Virus Res 2002 89 183 189
2. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. JM Walboomers MV Jacobs MM Manos FX Bosch JA Kummer KV Shah PJ Snijders J Peto CJ Meijer N Munoz, J Pathol 1999 189 12 19 (Pubitemid 29406813)
3. New epidemiology of human papillomavirus infection and cervical neoplasia. MH Schiffman, J Natl Cancer Inst 1995 87 1345 1347
4. Natural history of cervicovaginal papillomavirus infection in young women. GY Ho R Bierman L Beardsley CJ Chang RD Burk, N Engl J Med 1998 338 423 428 (Pubitemid 28135669)
5. Natural History and Possible Reactivation of Human Papillomavirus in Human Immunodeficiency Virus Positive Women. HD Strickler RD Burk M Fazzari K Anastos H Minkoff LS Massad C Hall M Bacon AM Levine DH Watts MJ Silverberg Xue Xiaonan NF Schlecht S Melnick JM Palefsky, J Nat Can Inst 2005 97 8 577 586 (Pubitemid 40723785)
6. Cancer and infection: estimates of the attributable fraction in 1990. P Pisani M Parkin N Mũoz J Ferlay, Cancer Epidemiol Biomarkers Prev 1997 6 387 400 (Pubitemid 27270542)
7. Global cancer statistics 2002. DM Parkin F Bray J Ferlay P Pisani, Cancer J Clin 2005 55 74 108
8. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load(1). I Heard JM Tassie V Schmitz L Mandelbrot MD Kazatchkine G Orth, Obstet Gynecol 2000 96 403 409 (Pubitemid 30674284)
9. Incidence of Cervical Squamous Intraepithelial Lesions in HIV-Infected Women. TV Ellerbrock MA Chiasson TJ Bush XW Sun D Sawo K Brudney TC Wright, JAMA 2000 283 1031 1037 (Pubitemid 30112217)
10. Natural history of cervicovaginal papillomavirus infection in young women. GYF Ho R Bierman L Beardsley CJ Chang RD Burk, N Engl J Med 1998 338 423 428 (Pubitemid 28135669)
11. Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV) positive and HIV-negative women. L Ahdieh RS Klein R Burk S Cu-Uvin P Schuman A Duerr M Safaeian J Astemborski R Daniel K Shah, J Infect Dis 2001 184 682 690 (Pubitemid 32826418)
12. A longitudinal study of HPV detection and cervical pathology in HIV-infected women. HA Cubie AL Seagar GJ Beattie S Monaghan AR Williams, Sex Transm Infect 2000 76 257 261 (Pubitemid 30690482)
13. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective: International Biological Study on Cervical Cancer (IBSCC) Study Group. FX Bosch MM Manos N Munoz M Sherman AM Jansen J Peto MH Schiffman V Moreno R Kurman KV Shah, J Natl Cancer Inst 1995 87 796 802
14. Human Papillomavirus Type 16 and Immune Status in Human Immunodeficiency Virus-Seropositive Women. HD Strickler JM Palefsky KV Shah K Anastos RS Klein H Minkoff A Duerr LS Massad DD Celentano C Hall M Fazzari S Cu-Uvin M Bacon P Schuman AM Levine AJ Durante S Gange S Melnick RD Burk, J Natl Cancer Inst 2003 95 1062 1071 (Pubitemid 36950110)
15. Long-term effect of highly active antiretroviral therapy on cervical lesions in HIV-positive women. C Uberti-Foppa D Ferrari S Lodini S Reina F Ameglio MA Grasso G Gallotta A Ferrari G Taccagni A Lazzarin FB Lillo, AIDS 2003 17 2136 2138 (Pubitemid 37297168)
16. Human papillomavirus infection and associated cervical disease in human immunodeficiency virus infected women: effect of highly active antiretroviral therapy. FB Lillo D Ferrari F Veglia M Origoni MA Grasso S Lodini E Mastrorilli G Taccagni A Lazzarin C Uberti-Foppa, J Infect Dis 2001 184 547 551 (Pubitemid 32783544)
17. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. SE Hawes CW Critchlow MA Faye Niang MB Diouf A Diop P Toure A Aziz Kasse B Dembele P Salif Sow AM Coll-Seck JM Kuypers NB Kiviat, J Infect Dis 2003 188 555 563 (Pubitemid 37011808)
18. Comparison of HPV test versus conventional and automation-asisted Pap screening as potential screening tools for preventing cervical cancer. P Nieminen S Vuorma M Viikki M Hakama A Antila, BJOG 2004 111 842 848 (Pubitemid 39061509)
19. The 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology. D Solomon D Davey R Kurman A Moriarty D O'Connor M Prey S Raab M Sherman D Wilbur TJ Wright N Young for the Forum Group Members and the Bethesda 2001, JAMA 2002 287 2114 2119 (Pubitemid 34437346)
20. Distribution of immune cell and cytokine producing cells in the uterine cervix of human papillomavirus infected women: influence of HIV-1 coinfection. AF Nicol ATG Fernandes B Grinsztejn F Russomano JR Lapa e Silva A Tristão M Pérez GJ Nuovo O Martínez-Maza MG Bonecini-Almeida, Diag Mol Pathol 2004 14 1 39 47
21. Statistical analysis of case-control studies. WD Thompson, Epidemiol Rev 1994 16 33 50 7925726 (Pubitemid 24217783)
22. HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. RM Jennifer H Margaret C Henri RA Bruce DC Diane R Lynn ED Lynette S Samuel W Anna-Lise, BMC Cancer 2006 6 135 141
23. Human papillomavirus genotypes associated with cervical cytologic abnormalities and HIV infection in Ugandan women. DB Blossom RH Beigi JJ Farrell W Mackay B Qadadri DR Brown S Rwambuya CJ Walker FS Kambugu FW Abdul-Karim CC Whalen RA Salata, J Med Virol 2007 79 6 758 765 (Pubitemid 46709371)
24. Prevalence of high-risk human papillomavirus types in Mexican women with cervical intraepithelial neoplasia and invasive carcinoma. R Lpez-Revilla LA Martínez-Contreras M Sánchez-Garza, Infectious Agents and Cancer 2008 3 3 10
25. Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human immunodeficiency virus infection. R Yamada T Sasagawa LW Kirumbi A Kingoro DK Karanja M Kiptoo GW Nakitare H Ichimura M Inoue, J Med Virol. 2008 80 5 847 855
26. Precancerous lesions of the uterine cervix in Pointe-Noire, Congo. D Moukassa A N'Golet LG Lingouala ML Eouani JB Samba JV Mambou S Ompaligoli LF Moukengue E Taty-Pambou, Med Trop (Mars). 2007 67 1 57 60 17506275 (Pubitemid 350157234)
27. Performance of cytology and colposcopy in diagnosis of cervical intraepithelial neoplasia (CIN) in HIV-positive and HIV-negative women. M Branca E Rossi M Alderisio G Migliore PL Morosini A Vecchione F Sopracordevole P Mudu L Leoncini K Syrjanen, Cytopathology 2001 12 84 93 (Pubitemid 32319938)
28. Immune response in cervical dysplasia induced by humanpapillomavirus: the influence of human immunodeficiency virus-1 co-infection Review. FN Alcina TGF Ana GB Maria da, Mem Inst Oswaldo Cruz, Rio de Janeiro 2005 100 1 1 12
29. Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6. A De Jong MIE van Poelgeest JM van der Hulst JW Drijfhout GJ Fleuren CJM Melief G Kenter R Offringa SH van der Burg, Cancer Res 2004 64 5449 5455 (Pubitemid 39006568)
30. USPHS/IDSA 1997 Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Centres for Disease Control, MMWR 1997 46 1 26